Kickoff meeting for investigator-initiated clinical trial of our ALS therapeutic candidate was held

The Department of Neurology at Sichuan University Huaxi Hospital held a kickoff meeting for the investigator-initiated clinical trial of an ALS therapeutic candidate discovered by SOCIUM Inc. (https://socium.co.jp/).

The meeting took place on October 22 at the Huaxi Hospital Neurological Disease Center on Sichuan University’s Jinjiang Campus. Attendees included Principal Investigator Professor Shang Huifang, the doctors in charge of the clinical trial, the CRA and CRO representatives, Sichuan University administrative staff, and SOCIUM Inc. CEO, Dr. Horimoto. During the meeting, the clinical trial protocol booklet was distributed. Following opening remarks by Professor Shang and Dr. Horimoto, one of the doctors in charge of the clinical trial explained the details of the trial protocol, and all participants conducted a final review and confirmation of the protocol.

Recruitment of trial participants has already commenced, targeting new patients and patients who have completed the washout period. This trial will enroll 20 ALS patients, set a 24-week treatment period, and evaluate the safety and efficacy of cycloserine inhibiting TDP43 aggregation for ALS treatment through a randomized, double-blind study.

Given Professor Shang’s reputation and the patient scale of Huaxi Hospital (4,900 beds), results are expected to be obtained early.